Profound Medical (PROF) Expected to Announce Quarterly Earnings on Thursday

Profound Medical (NASDAQ:PROF) is expected to be issuing its Q4 2025 results after the market closes on Thursday, March 5th. Analysts expect the company to announce earnings of ($0.28) per share and revenue of $10.5260 million for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, March 5, 2026 at 4:30 PM ET.

Profound Medical Price Performance

Shares of Profound Medical stock opened at $7.40 on Thursday. The stock has a market cap of $268.55 million, a PE ratio of -5.52 and a beta of 0.60. The firm has a fifty day moving average price of $7.46 and a 200 day moving average price of $6.24. Profound Medical has a 1 year low of $3.76 and a 1 year high of $8.95.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on PROF shares. Wall Street Zen upgraded Profound Medical from a “sell” rating to a “hold” rating in a research note on Sunday, November 23rd. Lake Street Capital raised their target price on Profound Medical from $11.00 to $12.00 and gave the stock a “buy” rating in a report on Wednesday, January 7th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Profound Medical in a report on Monday, December 29th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $12.00.

Hedge Funds Weigh In On Profound Medical

Large investors have recently bought and sold shares of the business. Alyeska Investment Group L.P. purchased a new position in Profound Medical during the fourth quarter worth approximately $5,340,000. Rosalind Advisors Inc. raised its stake in shares of Profound Medical by 54.4% during the 4th quarter. Rosalind Advisors Inc. now owns 1,068,955 shares of the company’s stock worth $8,413,000 after buying an additional 376,770 shares during the period. FIL Ltd lifted its position in shares of Profound Medical by 16.7% during the 4th quarter. FIL Ltd now owns 2,200,000 shares of the company’s stock valued at $17,270,000 after buying an additional 315,000 shares in the last quarter. Essex Investment Management Co. LLC acquired a new stake in Profound Medical in the 4th quarter valued at $2,437,000. Finally, Velan Capital Investment Management LP acquired a new stake in Profound Medical in the 4th quarter valued at $2,249,000. Institutional investors and hedge funds own 47.86% of the company’s stock.

About Profound Medical

Profound Medical Corp is a medical technology company headquartered in Toronto, Canada, that specializes in the development and commercialization of minimally invasive therapeutic solutions using magnetic resonance–guided ultrasound ablation. The company’s proprietary platform delivers focused ultrasound energy to targeted tissue under real-time MR imaging, offering a non-incisional alternative to traditional surgical approaches.

The company’s lead product, the TULSA-PRO system, is designed for the treatment of prostate conditions, including localized prostate cancer and benign prostatic hyperplasia.